Shift Health Advisory, LLC

shifthealthadv.com

We bring deep operating company experience driving results across complex, multi-stakeholder ecosystems - direct to consumer (DTC) and with an array of partners including health insurers, health systems, health technology, analytics and digital health companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMA TECH

ARROWHEAD PHARMACEUTICALS ANNOUNCES $25 MILLION MILESTONE PAYMENT FROM AMGEN

Arrowhead and Amgen | December 21, 2022

news image

Arrowhead Pharmaceuticals Inc. announced a $25M milestone payment from Amgen. This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma plc. “We are pleased with the great progress on the clinical development of olpasiran, which was develop...

Read More

Research

DARWINHEALTH ANNOUNCES SCIENTIFIC COLLABORATION WITH PRELUDE THERAPEUTICS IN ONCOLOGY

Prelude Therapeutics | October 13, 2021

news image

DarwinHealth, Inc. today announced a scientific research collaboration that uses its Biomarker Enrichment Strategies for Assays (BEST platform ) to elucidate novel biomarkers that guide translational trajectories of multiple cancer molecules being developed by Prelude Therapeutics. Under the collaboration, DarwinHealth will use its proprietary, quantitative, systems biology-based algorithms, CLIA-approved technologies, and validated approaches focused on Protein Master Regulator (...

Read More

Business Insights

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

news image

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More

Business Insights, PHARMACY MARKET

AQUESTIVE THERAPEUTICS EXPANDS LICENSE AND SUPPLY AGREEMENT WITH PHARMANOVIA FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO ADDITIONAL GLOBAL MARKETS

Globenewswire | March 30, 2023

news image

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for Libervant™ Buccal Film to cover the rest ...

Read More
news image

Business Insights, PHARMA TECH

ARROWHEAD PHARMACEUTICALS ANNOUNCES $25 MILLION MILESTONE PAYMENT FROM AMGEN

Arrowhead and Amgen | December 21, 2022

Arrowhead Pharmaceuticals Inc. announced a $25M milestone payment from Amgen. This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma plc. “We are pleased with the great progress on the clinical development of olpasiran, which was develop...

Read More
news image

Research

DARWINHEALTH ANNOUNCES SCIENTIFIC COLLABORATION WITH PRELUDE THERAPEUTICS IN ONCOLOGY

Prelude Therapeutics | October 13, 2021

DarwinHealth, Inc. today announced a scientific research collaboration that uses its Biomarker Enrichment Strategies for Assays (BEST platform ) to elucidate novel biomarkers that guide translational trajectories of multiple cancer molecules being developed by Prelude Therapeutics. Under the collaboration, DarwinHealth will use its proprietary, quantitative, systems biology-based algorithms, CLIA-approved technologies, and validated approaches focused on Protein Master Regulator (...

Read More
news image

Business Insights

CAN FITE ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB NASH CLINICAL TRIAL WITH NAMODENOSON

CordenPharma | February 01, 2022

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective of the trial is to evaluate the eff...

Read More
news image

Business Insights, PHARMACY MARKET

AQUESTIVE THERAPEUTICS EXPANDS LICENSE AND SUPPLY AGREEMENT WITH PHARMANOVIA FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO ADDITIONAL GLOBAL MARKETS

Globenewswire | March 30, 2023

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for Libervant™ Buccal Film to cover the rest ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us